โ† All deals

NEUROCRINE BIOSCIENCES INC

Public Equity (NASDAQ)BiotechnologyPublic CompanyNASDAQ
๐Ÿ“ San Diego, California, United Statesโ€ข Founded 1992โ€ข 2500 employees
StreetZero Signal 62
Be the first to signal interest

About NEUROCRINE BIOSCIENCES INC

Neurocrine Biosciences, Inc. is a public biotechnology company focused on discovering and developing treatments for central nervous system and endocrine-related disorders. Founded in 1992 and headquartered in San Diego, California, the company operates as a B2B pharmaceutical developer with lead programs including elagolix. It is listed on NASDAQ under the ticker NBIX and maintains a website at www.neurocrine.com.

LATEST FUNDINGRule 144
$2.5M
Announced 2026-11-17
TOTAL RAISED$1.29B
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for NEUROCRINE BIOSCIENCES INC.

Free plan includes 3 full deal profiles every month.

Key highlights

  • Publicly traded on NASDAQ (NBIX) with over 1.29B USD raised historically.
  • Completed a $2,479,650 Rule 144 placement.
  • Last major round was 1.00B USD post-IPO debt in 2026.
  • Focuses on CNS and endocrine drug development with partnerships such as AbbVie.
  • Reports strong financial metrics including 3.70B USD revenue and positive EPS growth.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account